Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
about
Glucagon and heart in type 2 diabetes: new perspectivesPotentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitusIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseDPP-4 inhibition and islet functionInduced-fit mechanism for prolyl endopeptidase.Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberineNutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar ratsEffect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in ratsEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesThe entero-insular axis: implications for human metabolism.Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique.Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.The incretin system and cardiometabolic diseaseSitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A Small-Scale Real-World Study.Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responsesVildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells.Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesSitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.Saxagliptin for type 2 diabetesInhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.Antimicrobial and hypoglycemic activities of novel N-Mannich bases derived from 5-(1-adamantyl)-4-substituted-1,2,4-triazoline-3-thionesVildagliptin improves endothelium-dependent vasodilatation in type 2 diabetesThe role of gut hormones in glucose homeostasisThe metabolic serine hydrolases and their functions in mammalian physiology and disease.Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass.Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesInhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation
P2860
Q26738580-E8F59254-48E6-4483-AA2A-031AB9302921Q26774021-711870E9-7807-4170-913E-70F2B81BF1E5Q26778608-356AC73B-FD54-45F8-B9EB-EB40F29A1F41Q27027920-9D3FB337-F5E3-4505-86A5-82CD1686A4BDQ27028127-96CCE3F0-1039-41CF-AB71-0D6A038A5CB5Q27661330-A512FFB8-4DE3-432E-ADCA-3D839D64E866Q28253310-EAECF8B7-84DD-4F59-961E-3D189766D180Q28564632-8F75BB30-7142-40FB-808A-0BD1F3A60A67Q28730724-AC92CDD3-1A3C-4677-8934-1A92FBB6D57BQ28762629-5625F69D-8332-4ABD-ADE2-E7161105C600Q30365939-003A1F45-8BA9-493A-9F8C-E0FFEBB22006Q33237060-110B79D1-0F7F-48FB-9A75-1F7D12A2D8D9Q33305182-4F73D565-2E17-45E7-959A-FE441B344DDEQ33334446-7FA62298-79DF-44DD-8EFF-CEC9AECA54EBQ33734024-58F9A13F-CFBB-4C06-938B-C8EEF7DE013FQ33751433-E1262190-E9DE-44AD-8574-18A3846CF28BQ33776092-C3264036-36EF-4C4F-A9B6-B8FE874E5CFEQ33785132-FC3F9B26-39C8-4C1C-962A-D66404351DB5Q33931373-76B4BC3F-FD44-48FE-AE0B-9A5E27718332Q33973990-563A5BFA-9951-41C8-ACA0-9AB6E9ABD60FQ34003019-CCC03C1B-F73F-424B-A573-09019A3B12BFQ34019325-3D42D30D-FBA0-466A-8E8A-592DB4F96CECQ34037472-6E4AC06D-BB31-446D-8979-42BF6765DB69Q34044817-9CE31010-A3F7-405C-8DF5-31CB13B57E4AQ34068749-D66FA494-C768-42F1-9C43-2428DC405587Q34128774-861333C4-A626-4F9E-8F44-89292A7F1FFDQ34265490-6FACCAD3-E049-4879-8381-344F7394339EQ34329204-EAFF52ED-2664-4AE2-A7F3-1A6627335F31Q34569365-0F6B4727-92DC-405B-9A5B-6AA41B866995Q34589793-4DB592D4-3B5B-4FDD-BCEA-734278D29634Q34620486-9A0E2BE5-71C0-4CD7-9536-31C0A3EDB252Q34620636-53E2BC8E-1555-464F-88EC-A85FACD3B5C2Q34835155-9B5DBAD0-6AD4-41C4-95F0-C8C585178234Q35179865-99A8A29E-3B50-4FDF-ABFE-5E63926DEA71Q35251016-57D4BF95-1C74-420A-9307-1BF46C2918B4Q35333042-FA5A0E2B-16F5-459B-BF76-95837F8DF370Q35756418-135D0585-7A74-4328-BEC2-3ED688D7D3FEQ35871904-7BBD9D9A-6A13-4981-AC1C-DF7974F19ADAQ35909303-48A212DD-8C88-449D-ADE9-A2300FE27830Q35916947-65D35AA3-69B1-45CA-BB2F-4FD7AE7F0447
P2860
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@ast
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@en
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@nl
type
label
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@ast
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@en
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@nl
prefLabel
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@ast
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@en
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@nl
P2093
P3181
P356
P1476
Inhibition of dipeptidyl pepti ...... agon levels in type 2 diabetes
@en
P2093
Anja Schweizer
David Holmes
Maria Svensson
Per-Anders Jansson
P304
P3181
P356
10.1210/JC.2003-031907
P407
P577
2004-05-01T00:00:00Z